/

Società

Fr

Non verificato

Fresenius Kabi

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaSaluteSanità

44 comunicati stampa

Guarda tutti i comunicati

15/10/2026

Fresenius Kabi Inducts 14 Honorees into National Blood Donation Hall of Fame

Fonte

Emittente

1.00

0

30/09/2026

Eventi

Farmaceutica

Oncologia

Sanità

Salute

Fresenius Kabi Receives Pharmacy Strategic Programs Excellence Award From Vizient®

Fonte

Emittente

1.00

0

06/09/2026

Fresenius Kabi and AABB Announce 21st Annual Blood Collectors Week, September 6–12, 2026, Honoring Lifesaving Blood Collection Professionals

Fonte

Emittente

1.00

0

03/09/2026

Fresenius Kabi Launches Generic Sugammadex in Simplist® Ready‑to‑Administer Prefilled Syringe in the U.S.

Fonte

Emittente

1.00

0

10/08/2026

Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials Due to Presence of Glass Particles

Fonte

Emittente

1.00

0

04/08/2026

Fresenius Kabi Issues Voluntary Nationwide Recall of One Lot of Morphine Sulfate Injection, USP in a Simplist® Prefilled Syringe Due to Labeling Mix-up

Fonte

Emittente

1.00

0

03/08/2026

Industria

Scienza

Igiene alimentare

Medicina - Varie

Biotecnologia

Sanità

Salute

Farmaceutica

Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market

Fonte

Emittente

1.00

0

31/07/2026

Industria

Biotecnologia

Igiene alimentare

Sanità

Salute

Farmaceutica

Scienza

Medicina - Varie

Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate

Fonte

Emittente

1.00

0

09/04/2026

Industria

Biotecnologia

Farmaceutica

Sanità

Salute

Igiene alimentare

HIV, AIDS e malattie autoimmuni

CMS Grants Fresenius Kabi COVID-19 Indication-Specific HCPCS Codes for Tyenne® (tocilizumab-aazg)

Fonte

Emittente

1.00

0

20/01/2026

Fresenius Kabi Recognized as a Top Employer in the United States for the Fourth Consecutive Year

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0